Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Low Risk ALL (LAL-BR/2001)
NCT00526175Phase 4Completed
- Sponsor
- Fundación PETHEMA
- Start
- Jun 2001
- Primary completion
- May 2015
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of prednisolone, vincristine, daunorubicin, asparaginase escherichia coli, cyclophosphamide in acute lymphoblastic leukemia (ALL), sponsored by Fundación PETHEMA. Started Jun 2001; status: completed.
02
Drugs
prednisolonevincristinedaunorubicinasparaginase escherichia colicyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00526175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00526175.